Earlier this week, news of a safety issue with Ariad Pharmaceuticals' (NASDAQ: ARIA) leukemia drug Iclusig caused the drugmaker's shares to plunge more than 65%. Today, the stock took another 20% tumble after the FDA announced that it is investigating the safety problems associated with the medication. In the following video, health-care analysts Max Macaluso and David Williamson discuss the details behind both of Ariad's drops this week.
Shares of Ariad plunged 70% earlier this week -- why did the shares drop another 20% today?
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo